Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Susan Branford

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

scientific article

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

scientific article published on 31 July 2017

BAM-matcher: a tool for rapid NGS sample matching

scientific article published on 3 May 2016

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

scientific article published on 05 July 2018

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI

scientific article published on 01 February 2019

CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy

scientific article

Chronic Myelogenous Leukemia: Monitoring Response to Therapy ⬇️

scientific article published on June 1, 2011

Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript

scientific article published on 28 September 2019

Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

scientific article published on 06 June 2020

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

scientific article

Continued therapeutic response monitoring in optimal responders with CML

scientific article published on December 1, 2012

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

scientific article published on 21 December 2006

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene

scientific article published on 27 October 2015

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

scientific article published on 25 April 2016

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

scientific article published on 8 June 2011

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan ⬇️

scientific article published on October 12, 2011

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase ⬇️

scientific article published on December 1, 2003

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

scientific article published on 03 August 2009

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

scientific article published on 23 September 2013

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini

scientific article published on 29 October 2012

International Reporting Scale of <i>BCR-ABL1</i> Fusion Transcript in Chronic Myeloid Leukemia: First Report from India ⬇️

scientific article published on January 12, 2012

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

scientific article published on 23 October 2015

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

scientific article published on 17 June 2019

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

scientific article published on 27 March 2019

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

scientific article published on 25 November 2019

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

scientific article

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

scientific article published on 12 October 2018

Minimal residual disease: the advantages of digital over analog polymerase chain reaction ⬇️

scientific article published on May 25, 2011

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

scientific article published on 09 April 2019

Molecular methods in diagnosis and monitoring of haematological malignancies ⬇️

scientific article published on October 1, 2011

Molecular monitoring in chronic myeloid leukemia-how low can you go?

scientific article published on December 2016

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

scientific article published on 7 March 2006

Monitoring after successful therapy for chronic myeloid leukemia

scientific article published on January 1, 2012

Monitoring and defining early response: Where to draw the line?

scientific article published on September 2016

Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?

scientific article published on January 1, 2012

Mutational analysis in chronic myeloid leukemia: when and what to do? ⬇️

scientific article published on March 1, 2011

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

scientific article

Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia ⬇️

scientific article published on October 1, 2010

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

scientific article

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

scientific article

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia

scientific article

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

scientific article published on 3 August 2017

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

scientific article published on 17 December 2014

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

scientific article published on 01 December 2019

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.

scientific article published on 22 March 2017

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

scientific article published on 11 January 2019

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

scientific article published on 14 January 2016

The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution

scientific article published on 14 May 2019

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.

scientific article published on 3 February 2018

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.

scientific article published on 10 May 2016

Paulina is supported by:

About Paulina

Help